PBP10

PBP10 (2 μM; 15 min) selectively binds to LTA, LPS, and PIP₂, but does not bind to PE^[1].
PBP10 (1-18 h) exhibits bactericidal activity against E. coli SG13009 with an MIC of 12.5 μg/mL, and also shows bactericidal activity against B. subtilis ATCC 6051 with an MIC of 3.125 μg/mL. Its bactericidal activity is strongly inhibited by LPS and LTA^[1].
PBP10 (0-50 μM) inhibits the directional migration of NIH3T3 fibroblasts, human A7 melanoma cells and human neutrophils in a concentration-dependent manner^[2].
PBP10 (1-50 μM) potently inhibits thrombin-stimulated human platelet aggregation and platelet actin assembly in a concentration-dependent manner^[2].
PBP10 (5-20 μM) concentration-dependently inhibits the migration speed and actin assembly of human neutrophils stimulated by fMLP^[2].
PBP10 (0-100 µg/mL; 24 h) exhibits extremely low cytotoxicity against human keratinocyte HaCaT cells^[3].
PBP10 (2-10 µg/mL; 1 h) exhibits potent dose-dependent bactericidal activity against E. coli RS218 and S. aureus A1^[3].
PBP10 (2-10 µg/mL; 24 h) dose-dependently inhibits the production of NO and ROS in human keratinocyte HaCaT cells stimulated by LPS (HY-D1056), LTA, heat-inactivated E. coli or heat-inactivated S. aureus^[3].
PBP10 (2-10 µg/mL; 24 h) reduces IL-8 release in LPS- and LTA-stimulated human keratinocyte HaCaT cells in a dose-dependent manner^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.